googletag.defineOutOfPageSlot('/23357399017/Offerwall-Ad-Unit-4ac7776188ac0199', 'div-gpt-ad-offerwall').addService(googletag.pubads());
DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Category Reports Biotech

Tickers reports and analysis

Vanda Pharmaceuticals Inc ($VNDA)

The FDA has approved BYSANTI™ (milsaperidone) tablets as a first-line atypical antipsychotic for the acute treatment of manic or mixed episodes in bipolar I disorder and for the treatment of schizophrenia in adults. This is Vanda’s second FDA approval in under two months, following NEREUS™ for motion-induced vomiting prevention.

Oscar Health Inc ($OSCR) Update 20 Feb

Tech-enabled health insurer focused on Affordable Care Act individual and small-group markets, trying to recover from a difficult 2025 with a 2026 guidance that points back toward operating profitability, under the shadow of U.S. healthcare policy and subsidy decisions.

ImmunityBio Inc ($IBRX) Update Feb 20

ImmunityBio announced a commercial partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA in Saudi Arabia and, over time, across the wider Middle East and North Africa, backed by an SFDA registration certificate with pricing. It’s not a new label approval, but it is a concrete step in the global monetization of the ANKTIVA franchise.

Tandem Diabetes Care Inc ($TNDM)

After crossing 1 billion dollars in annual revenue and reporting record gross margins, Tandem enters 2026 in a delicate transition phase: rolling out a pay-as-you-go pharmacy model, expanding direct international operations and pushing its Control-IQ+ automation to more patients, while still carrying net losses and a sizeable convertible note stack.

Solid Biosciences ($SLDB)

Solid Biosciences Inc. (NASDAQ: SLDB) is a precision genetic medicines company developing AAV‑based gene therapies for rare neuromuscular and cardiac diseases, with a lead focus on Duchenne muscular dystrophy (DMD), Friedreich’s ataxia (FA), and catecholaminergic polymorphic ventricular tachycardia (CPVT)

Corcept Therapeutics Inc ($CORT) Feb 19 Update

Quick EN/IT follow-up after the U.S. Court of Appeals for the Federal Circuit upheld the New Jersey decision that Teva’s proposed generic Korlym does not infringe two Corcept patents, clearing a key legal hurdle for generic competition. We look at what this means for Korlym cash flows, how it interacts with the recent relacorilant CRL and why the ovarian cancer PDUFA remains the central medium-term catalyst.

Hims & Hers Health Inc ($HIMS)

A deep dive into Hims & Hers after the GLP-1 “pill gambit”, the Novo Nordisk lawsuit, and the transformative acquisition of Eucalyptus: business model, financials, balance sheet, insiders, retail crowd and key catalysts for 2026–2027

Geron Corp ($GERN) Feb 18 Update

Almost one month after our long-form report at around $1.30, Geron is trading near $1.80. A slow but steady grind higher, driven more by positioning and expectations than by new hard data – with the first catalyst window now approaching: Q4 earnings and the first full-year RYTELO outlook under the new CEO.

NRX Pharmaceuticals Inc ($NRXP)

NRx Pharmaceuticals is a micro-cap biotech focused on severe psychiatric conditions: suicidal depression, bipolar depression with suicidality, PTSD and related disorders. The core of the story is NRX-100, a preservative-free intravenous ketamine program supported by a large Real-World Evidence dataset, and NRX-101, an oral D-cycloserine + lurasidone combination with Breakthrough designation. Around those assets, the company is building HOPE Therapeutics, a network of interventional psychiatry clinics that should both validate the care model and generate revenue.

ImmunityBio Inc ($IBRX) ANKTIVA in EU Ok!

European Commission Grants Final Conditional Marketing Authorization for ANKTIVA® in EU
Decision C(2026)1197: Final, binding authorization allowing commercial launch across 27 EU member states + Iceland, Norway, Liechtenstein for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Compass Pathways Plc ADR ($CMPS) Updated post CC

Release of new clinical data from two Phase 3 trials (COMP005 and COMP006) on COMP360 in TRD + management webcast
Tradable short-term event: additional clinical data (specific portions of studies) and official management narrative. This is the type of event that changes the perception of probability/quality of clinical evidence, and thus volatility too.

AI in Biotech 2026 $RXRX $TEM $EXAI

Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm.

Precision Biosciences Inc ($DTIL)

Next catalyst
H1 2026 – Updated ELIMINATE-B Phase 1/2 data in chronic hepatitis B (PBGENE-HBV), including higher-dose biopsy readouts.
Secondary 2026 catalyst: first sites activated and initial multi-patient data from the FUNCTION-DMD Phase 1/2 trial of PBGENE-DMD after FDA IND clearance (Study May Proceed) in February 2026.

Aldeyra Therapeutics (ALDX) PDUFA March 2026

Aldeyra Therapeutics (NASDAQ: ALDX) is a clinical-stage biotechnology company developing modulators of reactive aldehyde species (RASP) for immune-mediated and metabolic diseases. The key late-stage asset is reproxalap, an ophthalmic RASP modulator for dry eye disease (DED) and allergic conjunctiviti

Weekly Market Briefing (February 16–20, 2026)

Wall Street just closed a choppy week where enthusiasm about AI and data-center spend ran into valuation nerves, while inflation data kept the “soft landing” narrative alive. The coming days will be dominated by U.S. GDP, the Fed’s preferred inflation gauge (core PCE), fresh PMIs and a cluster of sector-specific catalysts across biotech, space, defense and AI small/mid caps.